Alan Christy Hunter

Alan Christy Hunter

Auto-generated profile, based on publicly available information

Alan Christy Hunter

Manchester Pharmacy School, University of Manchester, Manchester, UK

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2001 in Pharmacological Reviews
Verified
Journal Article
Closed access
Seyed Moein MoghimiSeyed Moein Moghimi
Seyed Moein Moghimi
AHA. Christy Hunter
A. Christy Hunter
JMJ. Clifford Murray
J. Clifford Murray

1 March 2005 in The FASEB Journal
Verified
Journal Article
Closed access
PDF file
Seyed Moein MoghimiSeyed Moein Moghimi
Seyed Moein Moghimi
AHA. Christy Hunter
A. Christy Hunter
JMJ. Clifford Murray
J. Clifford Murray

1 June 2005 in Molecular Therapy
Verified
Journal Article
Open access
Seyed Moein MoghimiSeyed Moein Moghimi
Seyed Moein Moghimi
PSPeter Symonds
Peter Symonds
JMJ. Clifford Murray
J. Clifford Murray
AHA. Christy Hunter
A. Christy Hunter
GDGrazyna Debska
Grazyna Debska
Adam SzewczykAdam Szewczyk
Adam Szewczyk
Poly(ethylenimine) (PEI) is a cationic macromolecule commonly used in gene transfer/therapy protocols with high transfection efficiency both in vitro and in vivo. PEI is also cytotoxic, but the molecular basis of its cytotoxicity is poorly understood. Here, we have demonstrated that branched (25 kDa) and linear (750 kDa) PEI can both induce membrane damage and initiate apoptosis in three clinically relevant human cell lines (Jurkat T cells, umbilical vein endothelial cells, and THLE3 hepatocyte-like cells). We have defined Phase I toxicity as early necrotic-like changes (30 min) resulting from compromised membrane integrity, assessed by considerable lactate dehydrogenase release and phosphatidylserine translocation from the inner plasma membrane to the outer cell surface. Phase II cytotoxicity (24 h) was due to activation of a "mitochondrially mediated apoptotic program," resulting from PEI-induced channel formation in the outer mitochondrial membrane. This led to the release of proapoptotic cytochrome c, subsequent activation of caspase 3, and alteration in mitochondrial membrane potential as a result of caspase translocation into the mitochondria. The reported observations have important implications for the design and execution of gene therapy protocols as well for controlling intracellular distribution of drugs with cationic-based polymer-delivery systems.

10 February 2012 in Annual Review of Pharmacology and Toxicology
Verified
Journal Article
Closed access
Seyed Moein MoghimiSeyed Moein Moghimi
Seyed Moein Moghimi
AHA.C. Hunter
A.C. Hunter
TAT.L. Andresen
T.L. Andresen
Intravenously injected nanoparticulate drug carriers provide a wide range of unique opportunities for site-specific targeting of therapeutic agents to many areas within the vasculature and beyond. Pharmacokinetics and biodistribution of these carriers are controlled by a complex array of interrelated core and interfacial physicochemical and biological factors. Pertinent to realizing therapeutic goals, definitive maps that establish the interdependency of nanoparticle size, shape, and surface characteristics in relation to interfacial forces, biodistribution, controlled drug release, excretion, and adverse effects must be outlined. These concepts are critically evaluated and an integrated perspective is provided on the basis of the recent application of nanoscience approaches to nanocarrier design and engineering. The future of this exciting field is bright; some regulatory-approved products are already on the market and many are in late-phase clinical trials. With concomitant advances in extensive computational knowledge of the genomics and epigenomics of interindividual variations in drug responses, the boundaries toward development of personalized nanomedicines can be pushed further.

1 December 2006 in Advanced Drug Delivery Reviews
Verified
Journal Article
Closed access
AHA Hunter
A Hunter

1 October 2000 in Trends in Biotechnology
Verified
Journal Article
Closed access
Seyed Moein MoghimiSeyed Moein Moghimi
Seyed Moein Moghimi
AHA.CHristy Hunter
A.CHristy Hunter